All In Biotech

Drug Trial Radar · NCT06307795

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS014004 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

63

Planned (sponsor's estimate)

Start

Jun 24, 2024

Primary completion

Apr 2027

Study completion Oct 2027

Sponsor

Sponsor type
Industry
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.

Conditions

  • Locally Advanced or Metastatic Solid Tumors

Interventions

  • ANS014004Drug

    Varying doses of ANS014004

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: From the time of first dose to 28 days post last dose of ANS014004
  2. Incidence of Serious Adverse Events (SAEs)Time frame: From time of first dose to 28 days post last dose of ANS014004
  3. Incidence of dose-limiting toxicities (DLT) as defined in the protocolTime frame: From time of first dose of ANS014004 to end of DLT period (approximately 30 days)
  4. Incidence of baseline laboratory finding, ECG and vital signs changesTime frame: From time of first dose to 28 days post last dose of ANS014004
  5. Proportion of patients with radiological response (ORR)Time frame: From date of first dose of ANS014004 until progression, or the last evaluable assessment in the absence of progression (approximately 2 years))

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California, San Diego

    San Diego, California · Recruiting

  • Sarah Cannon Research Institute

    Denver, Colorado · Recruiting

  • Advent Health

    Orlando, Florida · Recruiting

  • Henry Ford Health Cancer

    Detroit, Michigan · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • The University of Texas - MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology, Virginia

    Fairfax, Virginia · Recruiting

  • Swedish Cancer Institute

    Seattle, Washington · Recruiting

  • BC Cancer Vancouver Centre

    Vancouver, British Columbia, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Beijing Chest Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Not yet recruiting

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.